ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Uncategorized

TERAVOLT: Global Registry Investigates Outcomes Among Patients With Thoracic Cancer and COVID-19

on: June 08, 2020In: Uncategorized
TERAVOLT: Global Registry Investigates Outcomes Among Patients With Thoracic Cancer and COVID-19

By Marina Chiara Garassino, MD, and Leora Horn, MD, MSc, FRCPC Posted: June 9, 2020   Marina Chiara Garassino       Leora Horn   The new SARS-CoV-2 (COVID-19) virus […] Read more


Lung Cancer Considered – Episode XXV – Mar 16, 2020 Dr. Marty Edelman Speaks With IASLC President Dr. Tetsuya Mitsudomi

on: April 15, 2020In: Uncategorized
Lung Cancer Considered - Episode XXV - Mar 16, 2020 Dr. Marty Edelman Speaks With IASLC President Dr.
            Tetsuya Mitsudomi

Posted: April 16, 2020 In this latest episode of Lung Cancer Considered, the official podcast of the IASLC, Dr. Marty Edelman speaks with IASLC President Dr. Tetsuya Mitsudomi. Download the […] Read more

Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab

on: December 10, 2019In: Uncategorized
Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab

By Suresh Ramalingam, MD Posted: December 11, 2019 IN REFERENCE TO: Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non–Small-Cell Lung Cancer Treated […] Read more

JAVELIN Lung 200: Potential Reasons for Avelumab’s Failure to Provide OS Benefit

on: August 13, 2019In: Uncategorized
JAVELIN Lung 200: Potential Reasons for Avelumab’s Failure to Provide OS Benefit

By Hossein Borghaei, DO, MS Posted: August 14, 2019 In 2015, the use of checkpoint inhibitors in the second-line setting for metastatic lung cancer became the standard of care with the […] Read more

c-MET Antibody–Drug Conjugates: Misconceptions Corrected, Excitement Explained— An Interview with Dr. Karen Kelly

on: April 04, 2019In: Uncategorized
c-MET Antibody–Drug Conjugates: Misconceptions Corrected, Excitement Explained— An
            Interview with Dr. Karen Kelly

Posted: April 1, 2019 The first in-human study evaluating telisotuzumab vedotin (Teliso-V)—a c-MET antibody–drug conjugate formerly known as ABBV-399— has shown encouraging activity for patients with c-MET–positive NSCLC.1 Teliso-V combines the […] Read more

An Interview with Dr. Federico Cappuzzo: Checkpoint Inhibitors Have Replaced Old Strategies

on: February 25, 2019In: Uncategorized
An Interview with Dr. Federico Cappuzzo: Checkpoint Inhibitors Have Replaced Old Strategies

Posted: March 1, 2019 Federico Cappuzzo, MD, PhD, has been the director of Medical Oncology at AUSL della Romagna, Ravenna, Italy, since April 2016; in January 2017 he became the […] Read more

Thoughts on IMpower 150: Latest FDA Approval for Atezolizumab Misses the Mark

on: February 25, 2019In: Uncategorized
Thoughts on IMpower 150: Latest FDA Approval for Atezolizumab Misses the Mark

Posted: March 1, 2019 On December 6, 2018, the U.S. Food and Drug Administration (FDA) approved atezolizumab in combination with bevacizumab and chemotherapy, specifically paclitaxel and carboplatin, in advanced nonsquamous […] Read more

The IASLC Fight Against Lung Cancer in Peru and Latin America

on: November 08, 2018In: Uncategorized
The IASLC Fight Against Lung Cancer in Peru and Latin America

By Dr. Luis E. Raez, MD Posted: October 2018 Peru is one of the largest Latin American countries, with a population of approximately 28 million people. Cancer is not yet […] Read more

Dr. Howard 'Skip' Burris III Shares His Views on Clinical Trial Eligibility Criteria, Payer Involvement

on: June 01, 2018In: Uncategorized
Dr. Howard 'Skip' Burris III Shares His Views on Clinical Trial Eligibility Criteria, Payer Involvement

Posted: June 2018 Howard A. “Skip” Burris III, MD, is the chief medical officer and president of clinical operations at Sarah Cannon, the Cancer Institute of HCA Healthcare, where he […] Read more

Q&A with Dr. D. Ross Camidge

on: April 05, 2018In: Uncategorized
Q&A with Dr. D. Ross Camidge

Posted: April 2018 In January 2018, the response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group—an international collaboration of cancer treatment, scientific, and imaging experts— published a new guideline on […] Read more

1234

SEARCH ILCN

Archives

PROVIDER RESOURCES

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

INDUSTRY SUPPORTED


COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

INDUSTRY SUPPORTED

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy